RBC Raises Kymera Therapeutics Price Target to $116
RBC raised its price target on Kymera Therapeutics to $116 from $112 and maintained a Sector Perform rating with speculative risk.
RBC raised its price target on Kymera Therapeutics to $116 from $112 and maintained a Sector Perform rating with speculative risk.